For balancing effectiveness with cost and tolerability, single agonists might be better for some people
This was the knowledge from the previous GLP-1 project [at Novo Nordisk in the 90s] that led to liraglutide
In some cases, a plateau indicates that the maximum benefit from the current dose has been reached and clinical reassessment including dose titration or addressing lifestyle factors is warranted
For Contrave, common side effects can include nausea, constipation, headaches, dry mouth and insomnia
On the other hand, if theres minimal improvement after a fair trial (e.g., 48 doses over 2 months), guidelines would suggest discontinuing PT-141fda.gov and exploring other options
Special tests such as the omega-3 index (determination of the EPA/DHA content in the erythrocyte membrane) can indicate whether there is a deficiency of omega-3 fatty acids this is co-determined by some centers, as a low omega-3 index indicates a pro-inflammatory environment